Elon's Vision
  • Contacts
  • Privacy Policy
  • Terms & Conditions
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock
No Result
View All Result
Elon's Vision
No Result
View All Result
Home Editor's Pick

Overlicensed and Underused: Rethinking Pharmacy’s Role in Health Care

by
June 25, 2025
in Editor's Pick
0
Overlicensed and Underused: Rethinking Pharmacy’s Role in Health Care
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Jeffrey A. Singer

The American Society of Hospital Pharmacists (ASHP) launched its Practice Advancement Initiative (PAI) in 2010 and updated it in 2020 with PAI2030.

PAI 2030 is the ASHP’s initiative to improve how people access and use medications by expanding pharmacists’ roles in patient care, promoting the use of data and technology, and strengthening pharmacists’ leadership in safe medication use. The ASHP provides hospitals, clinics, and pharmacy training programs with clear goals, practical tools, and strategies to expand pharmacists’ responsibilities, integrate pharmacy teams into broader care, and track progress.

Today, the American Journal of Health-System Pharmacy published the results of the ASHP National Survey of Pharmacy Practice in Hospital Settings—Clinical Services and Workforce 2024. It surveyed pharmacy directors at 1,497 general and children’s hospitals across the country. The results:

Pharmacists routinely provide clinical pharmacy services to a majority of inpatients in over 75% of hospitals and are most commonly assigned to general medical-surgical (73.3%), critical care (68.5%), oncology (56.9%), cardiology (48.5%), infectious disease/​antimicrobial stewardship (48.1%) units and the emergency department (46.5%). Pharmacists independently prescribe in 18.5% of hospitals. Progress towards the ASHP Practice Advancement Initiative (PAI) 2030 goals has been mixed; except for technicians performing more advanced roles, measures have remained relatively stable over the past 5 years.

The authors of the paper concluded, “…inpatient and ambulatory care clinical pharmacy services continue to expand across the country, with most hospitals routinely providing care to a majority of patients in over three-quarters of hospitals.”

Pharmacists’ growing role in patient care extends beyond hospitals. When prescribing medication, physicians often consult pharmacists about potential drug interactions with the patient’s current medications. Pharmacists are well qualified to handle these inquiries because they frequently interact with many patients and receive as much classroom training as physicians.

The Doctor of Pharmacy (PharmD) degree has become the standard entry-to-practice degree for pharmacists in the US, replacing the Bachelor of Science in Pharmacy degree. Most state pharmacy boards require license applicants to hold a PharmD degree. It takes students four to six years to earn a PharmD degree. Their coursework includes biology, chemistry, physics, mathematics, pharmacology, and medical ethics.

In our 2024 briefing paper, Let Pharmacists Prescribe, Marc Joffe and I explain how policymakers in the UK, Australia, and Canada have expanded patients’ access to routine outpatient care through pharmacists. Instead of waiting for appointments in doctors’ offices, clinics, or urgent care centers, people can go to the many pharmacies where pharmacists test and treat common medical issues like urinary tract infections, strep throat, and allergic reactions; provide preventative measures such as HIV pre- and post-exposure prophylaxis, Lyme disease prophylaxis, and routine immunizations; and dispense hormonal contraceptives.

In 2018, Idaho became the first US state to adopt Alberta’s policy on pharmacist prescribing. Montana and Colorado have since followed suit. Pharmacy chains have started advertising test-and-treat services directly to consumers.

Pharmacists are highly trained health care professionals who could provide many more services to patients than licensing laws in many states permit. As I wrote in my book, Your Body, Your Health Care:

The various health professions regularly battle before state lawmakers over concerns about their scope of practice. Some entrenched incumbents jealously guard the scope of practice their licenses permit, resisting efforts by other professions to encroach on their domain. Each tries to persuade lawmakers about what services they believe it is safe for the government to allow patients to seek from competing professions.… Patients didn’t ask lawmakers to license health professionals. Patients have no say in the matter.

Expanding pharmacists’ scope of practice is a straightforward way to enhance access and decrease unnecessary bottlenecks in care. Ideally, states should eliminate all licensing laws. Third-party accrediting organizations can perform the functions of licensing boards. However, if that is not politically feasible, states don’t need to wait—Idaho and Alberta have already shown the way.

Previous Post

Wimbledon 2025: BQ Watches Unveils Top Watch Selections for the Ultimate Match

Next Post

“Stuttgart’s 17th Taicang Day Honors Three Decades of Sino-German Collaboration and Advancement”

Next Post

“Stuttgart’s 17th Taicang Day Honors Three Decades of Sino-German Collaboration and Advancement”

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!
  • Trending
  • Comments
  • Latest

Jay Bhattacharya on Public Health

October 12, 2021

That Bangladesh Mask Study!

December 1, 2021

Antitrust Regulation Assumes Bureaucrats Know the “Correct” Amount of Competition

November 24, 2021
Pints of champagne could be the next ‘Brexit dividend’

Pints of champagne could be the next ‘Brexit dividend’

December 24, 2021
Tesla’s European sales fall for a fifth month in a row

Tesla’s European sales fall for a fifth month in a row

0

0

0

0
Tesla’s European sales fall for a fifth month in a row

Tesla’s European sales fall for a fifth month in a row

June 25, 2025
Aston Martin resumes US exports after Trump tariffs lifted

Aston Martin resumes US exports after Trump tariffs lifted

June 25, 2025
Skoda overtakes Tesla in Europe as EV buyers turn to cheaper alternatives

Skoda overtakes Tesla in Europe as EV buyers turn to cheaper alternatives

June 25, 2025

Dismantling the Warfare State Was Never Going to Be Easy

June 25, 2025

Recent News

Tesla’s European sales fall for a fifth month in a row

Tesla’s European sales fall for a fifth month in a row

June 25, 2025
Aston Martin resumes US exports after Trump tariffs lifted

Aston Martin resumes US exports after Trump tariffs lifted

June 25, 2025
Skoda overtakes Tesla in Europe as EV buyers turn to cheaper alternatives

Skoda overtakes Tesla in Europe as EV buyers turn to cheaper alternatives

June 25, 2025

Dismantling the Warfare State Was Never Going to Be Easy

June 25, 2025

Disclaimer: ElonsVision.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

  • Contacts
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 ElonsVision. All Rights Reserved.

No Result
View All Result
  • News
  • Economy
  • Editor’s Pick
  • Investing
  • Stock

Copyright © 2025 ElonsVision. All Rights Reserved.